China Like most founders, my dream is to bring one of our own drugs to market and see patients genuinely benefit from our inventions Built on deep expertise in oligonucleotide chemistry, Leaderna Therapeutics is advancing a new generation of siRNA medicines for chronic diseases, with programmes spanning hypertension, dyslipidaemia and obesity.…
China Strong efficacy data attracts collaborators, but confidence shaken by other companies’ weaker results holds the whole field back Regend Therapeutics was founded in 2015 by Dr Ting Zhang and her husband, Professor Wei Zuo, to move stem cell research out of the lab and into patients. The company went on…
Korea Building stronger bridges between Korean biotech companies and global capital will be critical to unlocking the ecosystem’s full potential Chang Woo Lee, CEO of CUROGEN, discusses translating academic science into innovative medicines, developing multispecific proteins and an oral IBD therapy, and pursuing global expansion. He highlights Korea’s biotech strengths and…
Global The global contract manufacturing market is booming, but fragmented. The well-established names of the CDMO space – Lonza, Thermo Fisher, WuXi AppTec, WuXi Biologics, and Samsung Biologics – account for just 15 percent of total revenues. Beyond these giants, a huge network of smaller, more specialised CDMOs are, in…
Europe Genmab is moving into one of the most consequential chapters in its history, as decades of antibody innovation converge with an ambition to take greater ownership of the journey from science to patient. With a European commercial organisation taking shape, opening the way for independently led launches, and a late-stage…
Germany What begins as frustration with the limits of academic research has developed into a story of entrepreneurship, scientific translation and sustainable biotech growth. Dr Thomas Schirrmann, Co-Founder and CEO of YUMAB, reflects on building a therapeutic antibody specialist from Braunschweig without conventional venture capital, competing through scientific expertise and flexibility,…
China Excalipoint is betting that the next chapter of T-cell engagers will be written in solid tumours, where the modality is beginning to challenge the boundaries of cancer immunotherapy. Co-Founder, Chairman and CEO/CSO Dr Lei Fang explains how two decades of T-cell research underpin a differentiated pipeline, a China-first global development…
China CirCode Biomed is emerging at the forefront of a small but fast-evolving field seeking to turn circular RNA into a new class of medicines. From its roots in pioneering academic research, the Chinese biotech has moved circRNA into the clinic while building a diversified pipeline across ischaemic disease, in vivo…
Europe The European Union is in the midst of the biggest shake-up of its pharmaceutical rulebook in a generation, racing to secure supply chains, speed up drug development, and keep Europe competitive against the US and Asia; all without loosening the safety net patients rely on. Sandra Gallina, Director-General for Health…
USA Innovation cannot stop at the laboratory door. It must extend to how therapies are developed, approved, and reimbursed Brian Campbell, Vice President and General Manager of the US for Orchard Therapeutics, A Kyowa Kirin Company, discusses the critical role of newborn screening in identifying patients with metachromatic leukodystrophy (MLD), a…
Korea Korea’s real strength right now is active, innovative discovery research, and that expertise, along with international networking, keeps improving Jungwon Woo, MedPacto CEO, discusses translating innovative cancer research into clinical development, with a focus on TGF-beta and tumour microenvironment targeting. She highlights MP010’s potential, early clinical progress and partnership opportunities,…
Korea What I want, more than anything, is to introduce this modality to patients as quickly and as properly as possible Jaejin Cho, CEO of CellinCells, explains how the company’s proprietary Tissue Reforming Technology Platform (TRTP) translates developmental biology and quantitative tissue design into scaffold-free therapeutic tissue modules. He discusses the…
See our Cookie Privacy Policy Here
